

Jonathan Kay

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6687996/jonathan-kay-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

155
papers

12,911
citations

42
h-index

113
g-index

176
ext. papers

15,373
ext. citations

6.9
avg, IF

5.97
L-index

#	Paper	IF	Citations
155	Development of a screening tool to identify patients with axial spondyloarthritis: a cognitive interview study.. <i>Clinical Rheumatology</i> , 2022 , 1	3.9	0
154	The disease burden of axial spondyloarthritis: through a gendered lens.. <i>Clinical Rheumatology</i> , 2022 , 1	3.9	0
153	Physical Activity and Attitudes Toward Exercise in People With Axial and Peripheral Spondyloarthritis. <i>Journal of Rheumatology</i> , 2021 , 48, 513-519	4.1	0
152	Knowledge of biosimilars and perceptions of the naming conventions for biosimilar products in clinical practice in the United States. <i>Drugs and Therapy Perspectives</i> , 2021 , 37, 338-346	1.5	
151	Pharmacokinetic equivalence of CT-P17 to high-concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects. <i>Clinical and Translational Science</i> , 2021 , 14, 1280-1291	4.9	9
150	AB0198 EFFICACY AND SAFETY AFTER TRANSITION FROM REFERENCE ADALIMUMAB TO CT-P17 (ADALIMUMAB BIOSIMILAR: 100 MG/ML) IN COMPARISON WITH THE MAINTAINED TREATMENT (CT-P17 OR REFERENCE ADALIMUMAB) IN PATIENTS WITH MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS: 1-YEAR RESULT. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1123-1124	2.4	1
149	AB0892-HPR PATIENT PERSPECTIVES ON PROVIDER PRACTICES LEADING TO AN AXIAL SPONDYLOARTHRTIS DIAGNOSIS: A QUALITATIVE STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1469.2-1470	2.4	
148	Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 4323-4333	3.8	6
147	Personal Experiences with Diagnostic Delay Among Axial Spondyloarthritis Patients: A Qualitative Study. <i>Rheumatology and Therapy</i> , 2021 , 8, 1015-1030	4.4	2
146	POS1474-HPR PERSONAL EXPERIENCES WITH DIAGNOSTIC DELAY AMONG AXIAL SPONDYLOARTHRTIS PATIENTS IA QUALITATIVE STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1022.2-1022	2.4	
145	Primary care physician perspectives on screening for axial spondyloarthritis: A qualitative study. <i>PLoS ONE</i> , 2021 , 16, e0252018	3.7	2
144	Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomised study in rheumatoid arthritis. <i>Rheumatology</i> , 2021 ,	3.9	4
143	Knowledge of biosimilars and perceptions of the naming conventions for biosimilar products in clinical practice in the United States. <i>Drugs and Therapy Perspectives</i> , 2021 , 37, 338-346	1.5	0
142	Healing of erosions in rheumatoid arthritis remains elusive: results with 24 months of the anabolic agent teriparatide. <i>Scandinavian Journal of Rheumatology</i> , 2021 , 50, 11-14	1.9	1
141	Disease Burden and Health-Related Quality of Life Among Women and Men with Spondyloarthritis: An Exploratory Analysis of a Population-Based Sample. <i>Journal of Women's Health</i> , 2021 , 30, 1637-1644	3	1
140	Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	22
139	Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study. <i>Arthritis Research and Therapy</i> , 2021 , 23, 51	5.7	11

138	Patient perspectives on health care provider practices leading to an axial spondyloarthritis diagnosis: an exploratory qualitative research study.. <i>BMC Family Practice</i> , 2021 , 22, 251	2.6	
137	Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1067-1071	9.5	6
136	Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States?. <i>BioDrugs</i> , 2020 , 34, 723-732	7.9	4
135	Overcoming barriers to biosimilars in inflammatory arthritis. <i>Nature Reviews Rheumatology</i> , 2020 , 16, 65-66	8.1	2
134	Physical activity and attitudes and perceptions towards physical activity in patients with spondyloarthritis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 289-302	5.3	3
133	Primary care physician perspectives on barriers to diagnosing axial Spondyloarthritis: a qualitative study. <i>BMC Family Practice</i> , 2020 , 21, 204	2.6	8
132	Examining Treatment Decision-Making Among Patients With Axial Spondyloarthritis: Insights From a Conjoint Analysis Survey. <i>ACR Open Rheumatology</i> , 2020 , 2, 391-400	3.5	4
131	A Time-Response Measure to Assess Clinical Equivalence in Rheumatoid Arthritis: An Assessment Using Data From Clinical Trials of Biosimilars. <i>Statistics in Biopharmaceutical Research</i> , 2020 , 1-13	1.2	
130	Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib. <i>RMD Open</i> , 2020 , 6,	5.9	6
129	Clinical trial and Real-worldRdata support switching from a bio-originator to its biosimilar. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e44	2.4	3
128	Hand Rheumatoid Arthritis 2020 , 179-184		
127	Are There Benefits and Risks to Biosimilars from a Patient Perspective?. <i>Rheumatic Disease Clinics of North America</i> , 2019 , 45, 465-476	2.4	3
126	A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1101-1111	9.5	41
125	PANLAR consensus statement on biosimilars. <i>Clinical Rheumatology</i> , 2019 , 38, 1485-1496	3.9	5
124	Patient Concerns and Perceptions Regarding Biologic Therapies in Ankylosing Spondylitis: Insights From a Large-Scale Survey of Social Media Platforms. <i>Arthritis Care and Research</i> , 2019 , 71, 323-330	4.7	10
123	Biosimilars in Dermatology: Analytical, Regulatory, and Clinical Considerations: A Treatise From the Medical Board of the National Psoriasis Foundation. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019 , 4, 125-132	1.1	1
122	The "Treat to Target" Approach to Rheumatoid Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2019 , 45, 487-504	2.4	8
121	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 872-878	2.4	11

120	Anti-cyclic citrullinated peptide antibodies, other common autoantibodies, and smoking as risk factors for lymphoma in patients with rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2018 , 47, 270-275	1.9	1
119	The Science Behind Biosimilars: Entering a New Era of Biologic Therapy. <i>Arthritis and Rheumatology</i> , 2018 , 70, 334-344	9.5	23
118	Reply. <i>Arthritis and Rheumatology</i> , 2018 , 70, 476	9.5	
117	Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 165-174	2.4	120
116	e48 Effects of baricitinib on haematological laboratory parameters in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2018 , 57,	3.9	3
115	Treat-to-target (T2T) recommendations for gout. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 632-638	2.4	70
114	Biosimilars: implications for rheumatoid arthritis therapy. <i>Current Opinion in Rheumatology</i> , 2017 , 29, 260-268	5.3	17
113	Effects of Teriparatide on Joint Erosions in Rheumatoid Arthritis: A Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1741-1750	9.5	24
112	Pharmacotherapy: Biosimilar switching - "To set a form upon desired change". <i>Nature Reviews Rheumatology</i> , 2017 , 13, 391-392	8.1	5
111	Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naïve patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1279-1284	2.4	51
110	Gadolinium-Induced Fibrosis. <i>Rare Diseases of the Immune System</i> , 2017 , 209-237	0.2	
109	Differential Effects of Inflammation on Bone and Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis. <i>Current Rheumatology Reports</i> , 2016 , 18, 72	4.9	9
108	Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2016 , 43, 2120-2130	4.1	26
107	THU0138 Secondary Efficacy Results Up To Week 24 from A Phase III Study Comparing SB5 (An Adalimumab Biosimilar) with Adalimumab Reference Product in Patients with Moderate To Severe Rheumatoid Arthritis despite Methotrexate Therapy. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 231.1-231	2.4	
106	Brief Report: Development and Validation of a Semiautomated Method to Measure Erosion Volume in Inflammatory Arthritis by Computed Tomography Scanning. <i>Arthritis and Rheumatology</i> , 2016 , 68, 332-6	9.5	4
105	Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy. <i>International Journal of Rheumatic Diseases</i> , 2016 , 19, 1143-1156	2.3	7
104	The term Non-radiographic axial spondyloarthritis is much more important to classify than to diagnose patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 791-4	2.4	72
103	Gadolinium-Induced Fibrosis. <i>Annual Review of Medicine</i> , 2016 , 67, 273-91	17.4	48

102	The changing landscape of biosimilars in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 974-824	124
101	Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1081-91	2.4 119
100	Differential Expression of Hedgehog and Snail in Cutaneous Fibrosing Disorders: Implications for Targeted Inhibition. <i>American Journal of Clinical Pathology</i> , 2016 , 146, 709-717	1.9 9
99	Imaging for Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome. <i>Rheumatic Disease Clinics of North America</i> , 2016 , 42, 695-710	2.4 28
98	Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. <i>Arthritis Research and Therapy</i> , 2015 , 17, 14	5.7 37
97	Biosimilars in rheumatology: current perspectives and lessons learnt. <i>Nature Reviews Rheumatology</i> , 2015 , 11, 713-24	8.1 77
96	Biosimilars in rheumatology: what the clinician should know. <i>RMD Open</i> , 2015 , 1, e000010	5.9 35
95	Gadolinium-based compounds induce NLRP3-dependent IL-1 β production and peritoneal inflammation. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 2062-9	2.4 29
94	Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 538-46	2.4 65
93	Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1051-7	2.4 106
92	SAT0151 Safety Profile of BOW015, A Biosimilar Infliximab, In Healthy Subjects and Patients with Active Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 706.2-706	2.4 1
91	Utilizing the METEOR initiative to improve rheumatoid arthritis patient care. <i>International Journal of Clinical Rheumatology</i> , 2015 , 10, 425-431	1.5
90	Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians: Differences Across Countries in the METEOR Database. <i>Journal of Clinical Rheumatology</i> , 2015 , 21, 349-54 ¹	1.1 6
89	Miscellaneous arthropathies 2015 , 1420-1431	
88	Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year. <i>Arthritis Research and Therapy</i> , 2014 , 16, R40	5.7 71
87	Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 62-8	2.4 467
86	Current status of nephrogenic systemic fibrosis. <i>Clinical Radiology</i> , 2014 , 69, 661-8	2.9 79
85	THU0444 Assessment of Global Disease Activity in RA by Patients and Physicians: Cultural Differences across Countries in the Meteor Database. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 336.2-336	2.4 1

84	Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control study. <i>Rheumatology</i> , 2014 , 53, 1613-7	3.9	8
83	OP0012 A Phase 3, Randomized, Double-Blind, Active Comparator Study of the Efficacy and Safety of Bow015, A Biosimilar Infliximab, in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Doses. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 64.1-64	2.4	4
82	Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1811-8	2.4	25
81	Nephrogenic Systemic Fibrosis 2014 , 247-254		
80	Rituximab biosimilars. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 1049-62	5.4	30
79	Relapsing polychondritis. <i>Rheumatic Disease Clinics of North America</i> , 2013 , 39, 263-76	2.4	36
78	The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. <i>Rheumatology</i> , 2013 , 52, 1845-55	3.9	18
77	Validation of a screening instrument for nephrogenic systemic fibrosis. <i>Arthritis Care and Research</i> , 2013 , 65, 637-42	4.7	2
76	Systemic sclerosis without antinuclear antibodies or Raynaud's phenomenon: a multicentre study in the prospective EULAR Scleroderma Trials and Research (EUSTAR) database. <i>Rheumatology</i> , 2013 , 52, 560-7	3.9	15
75	FRI0096 Haq baseline values in an international registry of ra patients during the era of biologic therapies: the 2013 meteor database.. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A402.1-A402	2.4	
74	THU0202 Five-Year Safety and Efficacy of Golimumab in Patients with Active Rheumatoid Arthritis Despite Previous Anti-Tumor Necrosis Factor Therapy: Final Study Results of the Phase 3, Randomized, Placebo-Controlled Go-After Trial. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A232.1-A232	2.4	2
73	Fibrosis-associated single-nucleotide polymorphisms in TGFB1 and CAV1 are not associated with the development of nephrogenic systemic fibrosis. <i>American Journal of Dermatopathology</i> , 2013 , 35, 351-6	0.9	3
72	FRI0211 Safety and efficacy of subcutaneous golimumab in chinese patients with active rheumatoid arthritis despite mtx therapy: results from a randomized, placebo-controlled, phase 3 trial. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A444.2-A444	2.4	4
71	Evolution of treatment for rheumatoid arthritis. <i>Rheumatology</i> , 2012 , 51 Suppl 6, vi28-36	3.9	96
70	Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure. <i>Best Practice and Research in Clinical Rheumatology</i> , 2012 , 26, 489-503	5.3	65
69	Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012. <i>Biologics</i> , 2012 , 40, 517-27	1.8	16
68	The advent of biosimilar therapies in rheumatology--"O brave new world". <i>Nature Reviews Rheumatology</i> , 2012 , 8, 430-6	8.1	79
67	Sensorineural hearing loss following imatinib (Gleevec) administration. <i>Otolaryngology - Head and Neck Surgery</i> , 2012 , 146, 335-7	5.5	10

66	ACR/EULAR 2010 rheumatoid arthritis classification criteria. <i>Rheumatology</i> , 2012 , 51 Suppl 6, vi5-9	3.9	172
65	Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1671-9	2.4	46
64	Quantitative assessment of dermal cellularity in nephrogenic systemic fibrosis: a diagnostic aid. <i>Journal of the American Academy of Dermatology</i> , 2011 , 64, 741-7	4.5	12
63	Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. <i>Journal of the American Academy of Dermatology</i> , 2011 , 65, 1095-1106.e7	4.5	129
62	Assessment of control of rheumatoid arthritis disease activity. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011 , 25, 497-507	5.3	15
61	Treating rheumatoid arthritis to target: an international initiative. <i>Current Reviews in Musculoskeletal Medicine</i> , 2011 , 4, 79-83	4.6	
60	Diabetes mellitus and insulin resistance in patients with rheumatoid arthritis: risk reduction in a chronic inflammatory disease. <i>Arthritis Care and Research</i> , 2011 , 63, 512-21	4.7	62
59	Biosimilars: a regulatory perspective from America. <i>Arthritis Research and Therapy</i> , 2011 , 13, 112	5.7	39
58	Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. <i>Radiology</i> , 2011 , 260, 105-11	20.5	119
57	A 65-Year-Old Woman with Hardened Skin, Joint Contractures, and Yellow Scleral Plaques 2011 , 85-94		
56	Gadolinium and systemic fibrosis: guilt by association. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1895-7.4		15
55	Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention. <i>Rheumatic Disease Clinics of North America</i> , 2010 , 36, 385-404	2.4	132
54	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase I. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1589-95	2.4	117
53	Rheumatic manifestations of diabetes mellitus. <i>Rheumatic Disease Clinics of North America</i> , 2010 , 36, 681-99	2.4	65
52	2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1580-8	2.4	2158
51	Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. <i>Core Evidence</i> , 2010 , 4, 159-70	4.9	20
50	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2582-91		182
49	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2569-81		4825

48	Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients. <i>Radiology</i> , 2009 , 253, 81-9	20.5	85
47	E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy. <i>Journal of Rheumatology</i> , 2009 , 36, 1371-9	4.1	27
46	Case records of the Massachusetts General Hospital. Case 37-2009. A 46-year-old woman with chronic renal failure, leg swelling, and skin changes. <i>New England Journal of Medicine</i> , 2009 , 361, 2166-76	59.2	9
45	CMR2009: 5.04: Post-mortem analysis of gadolinium distribution in NSF subjects. <i>Contrast Media and Molecular Imaging</i> , 2009 , 4, 274-274	3.2	1
44	Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients. <i>Journal of Magnetic Resonance Imaging</i> , 2009 , 30, 1335-40	5.6	30
43	Physician ability to assess rheumatoid arthritis disease activity using an electronic medical record-based disease activity calculator. <i>Arthritis and Rheumatism</i> , 2009 , 61, 495-500		11
42	A rheumatology-specific informatics-based application with a disease activity calculator. <i>Arthritis and Rheumatism</i> , 2009 , 61, 488-94		12
41	Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. <i>Lancet, The</i> , 2009 , 374, 210-21	40	416
40	Nephrogenic systemic fibrosis: a pathologic study of autopsy cases. <i>Archives of Pathology and Laboratory Medicine</i> , 2009 , 133, 1943-8	5	32
39	Nephrogenic Fibrosing Dermopathy: A Review of the Massachusetts General Hospital Experience. <i>Journal of Cutaneous Pathology</i> , 2008 , 32, 89-89	1.7	
38	Case records of the Massachusetts General Hospital. Case 6-2008. A 46-year-old woman with renal failure and stiffness of the joints and skin. <i>New England Journal of Medicine</i> , 2008 , 358, 827-38	59.2	51
37	Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67 Suppl 3, iii66-9	2.4	27
36	Nephrogenic systemic fibrosis: an epidemic of gadolinium toxicity. <i>Current Rheumatology Reports</i> , 2008 , 10, 195-204	4.9	23
35	Non-crystalline and crystalline rheumatic disorders in chronic kidney disease. <i>Current Rheumatology Reports</i> , 2008 , 10, 235-48	4.9	10
34	What Causes Nephrogenic Systemic Fibrosis?. <i>Dialysis and Transplantation</i> , 2008 , 37, 95-98		2
33	Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. <i>Arthritis and Rheumatism</i> , 2008 , 58, 964-75		212
32	Imatinib mesylate treatment of nephrogenic systemic fibrosis. <i>Arthritis and Rheumatism</i> , 2008 , 58, 2543-8		124
31	Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. <i>Arthritis and Rheumatism</i> , 2007 , 56, 3433-41		158

30	Vascular Occlusion and Cardiac Conduction Disturbances in a Patient Undergoing Peritoneal Dialysis. <i>Seminars in Dialysis</i> , 2007 , 6, 135-139	2.5	1
29	Shoulder Pain in the Dialysis Patient. <i>Seminars in Dialysis</i> , 2007 , 8, 105-121	2.5	
28	Wegener's granulomatosis: is biologic therapy useful?. <i>Current Rheumatology Reports</i> , 2006 , 8, 303-11	4.9	6
27	Case records of the Massachusetts General Hospital. Case 39-2006. A 24-year-old woman with systemic lupus erythematosus, seizures, and right arm weakness. <i>New England Journal of Medicine</i> , 2006 , 355, 2678-89	59.2	17
26	Case records of the Massachusetts General Hospital. Case 4-2006. A 79-year-old woman with myalgias, fatigue, and shortness of breath. <i>New England Journal of Medicine</i> , 2006 , 354, 623-30	59.2	6
25	Case records of the Massachusetts General Hospital. Case 31-2005. A 60-year-old man with skin lesions and renal insufficiency. <i>New England Journal of Medicine</i> , 2005 , 353, 1605-13	59.2	13
24	Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-2004. A 68-year-old man with end-stage renal disease and thickening of the skin. <i>New England Journal of Medicine</i> , 2004 , 351, 2219-27	59.2	37
23	The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. <i>British Journal of Rheumatology</i> , 2004 , 43 Suppl 3, iii2-iii9		145
22	Advanced glycation endproducts and osteoarthritis. <i>Current Rheumatology Reports</i> , 2003 , 5, 33-40	4.9	54
21	Regression of lymphoproliferative disorder after treatment for hepatitis C virus infection in a patient with partial trisomy 3, Bcl-2 overexpression, and type II cryoglobulinemia. <i>Blood</i> , 2002 , 99, 2259-61	2.2	60
20	beta(2)-Microglobulin modified with advanced glycation end products delays monocyte apoptosis. <i>Kidney International</i> , 2001 , 59, 990-1002	9.9	59
19	The association of relapsing polychondritis and myelodysplastic syndrome: report of three cases. <i>Journal of Clinical Rheumatology</i> , 2000 , 6, 146-9	1.1	8
18	Osteoarticular disorders of renal origin: disease-related and iatrogenic. <i>Best Practice and Research in Clinical Rheumatology</i> , 2000 , 14, 285-305	5.3	21
17	Beta 2-microglobulin amyloidosis in renal failure: understanding this recently recognized condition. <i>Cleveland Clinic Journal of Medicine</i> , 1999 , 66, 145-7	2.8	4
16	Beta 2-microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts. <i>Kidney International</i> , 1998 , 53, 1365-73	9.9	72
15	Aminoguanidine inhibits advanced glycation end products formation on beta2-microglobulin. <i>Journal of the American Society of Nephrology: JASN</i> , 1998 , 9, 277-83	12.7	19
14	Development of gastrointestinal beta2-microglobulin amyloidosis correlates with time on dialysis. <i>American Journal of Surgical Pathology</i> , 1998 , 22, 729-35	6.7	27
13	β-microglobulin amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 1997 , 4, 187-211	2.7	11

12	Interaction between beta 2-microglobulin and advanced glycation end products in the development of dialysis related-amyloidosis. <i>Kidney International</i> , 1997 , 51, 1514-9	9.9	49
11	Performance characteristics of a dialysis-related amyloidosis questionnaire. <i>Journal of the American Society of Nephrology: JASN</i> , 1996 , 7, 1235-40	12.7	8
10	Enhancement of human monocyte beta-glucan receptors by glucocorticoids. <i>Immunology</i> , 1994 , 81, 96-102	10.8	11
9	Lyme disease. <i>Comprehensive Therapy</i> , 1993 , 19, 157-62		
8	Musculoskeletal manifestations in beta 2-microglobulin amyloidosis. Case discussion. <i>Arthritis and Rheumatism</i> , 1992 , 35, 592-602		11
7	Utility of high-resolution ultrasound for the diagnosis of dialysis-related amyloidosis. <i>Arthritis and Rheumatism</i> , 1992 , 35, 926-32		39
6	Identification and characterization of opsonic fibronectin in synovial fluids of patients with active rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1991 , 34, 687-96		4
5	Isolation and characterization of beta-glucan receptors on human mononuclear phagocytes. <i>Journal of Experimental Medicine</i> , 1991 , 173, 1511-20	16.6	151
4	Activation of CD4 cells by fibronectin and anti-CD3 antibody. A synergistic effect mediated by the VLA-5 fibronectin receptor complex. <i>Journal of Experimental Medicine</i> , 1989 , 170, 1133-48	16.6	254
3	Anesthesia for open lung biopsy in a patient with intracardiac tumor. <i>Anesthesiology</i> , 1989 , 71, 607-10	4.3	2
2	Synovial fluid eosinophilia in Lyme disease. <i>Arthritis and Rheumatism</i> , 1988 , 31, 1384-9		21
1	Separation of functionally distinct subpopulations of <i>Corynebacterium parvum</i> -activated macrophages with predominantly stimulatory or suppressive effect on the cell-mediated cytotoxic T cell response. <i>Cellular Immunology</i> , 1979 , 42, 28-41	4.4	31